Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03278665
Title 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE)
Acronym SENSITIZE
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors 4SC AG
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA | DEU


No variant requirements are available.